To comprehensively evaluate the efficacy of DGSY, we selected the absolute changes in serum ALT activity, LSM, BMI, blood lipids, blood glucose, and insulin resistance index as the secondary efficacy evaluation index. The gene discussed is GPT; the disease is Insulin resistance.